Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma

Background No report has evaluated axitinib-induced proteinuria as a biomarker for predicting treatment efficacy and survival of patients with metastatic renal cell carcinoma (mRCC). Methods The subjects were patients with mRCC treated with axitinib at Kinki University Hospital from February 2008 to...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2016-08, Vol.21 (4), p.748-755
Main Authors: Nozawa, Masahiro, Sugimoto, Koichi, Ohzeki, Takayuki, Minami, Takafumi, Shimizu, Nobutaka, Adomi, Shogo, Saito, Yoshitaka, Nose, Kazuhiro, Yoshimura, Kazuhiro, Uemura, Hirotsugu
Format: Article
Language:English
Subjects:
Adult
Aged
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - adverse effects
Biomarkers
Cancer Research
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Disease-Free Survival
Female
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Indazoles - administration & dosage
Indazoles - adverse effects
Kidney cancer
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Proteinuria - chemically induced
Retrospective Studies
Surgical Oncology
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background No report has evaluated axitinib-induced proteinuria as a biomarker for predicting treatment efficacy and survival of patients with metastatic renal cell carcinoma (mRCC). Methods The subjects were patients with mRCC treated with axitinib at Kinki University Hospital from February 2008 to November 2014. Clinical records were retrospectively reviewed including baseline patient characteristics, time-dependent changes of urinary protein status, computed tomography scans of metastatic lesions, treatment duration with axitinib, and survival time. Results A total of 45 patients were evaluable. Median tumor shrinkage rates were 32.3 and 35.0 % in patients with urinary protein increases ≥+2 and
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-015-0933-1